Leerink Partners Maintains Outperform on Nanobiotix, Raises Price Target to $46
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Leerink Partners analyst Jonathan Chang maintains Nanobiotix (NASDAQ:NBTX) with a Outperform and raises the price target from $37 to $46.
Leerink Partners analyst Jonathan Chang maintains Nanobiotix (NASDAQ:NBTX) with a Outperform and raises the price target from $37 to $46.